Recombinant Mouse APRIL - 5 μg

APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, is a critical member of the tumor necrosis factor (TNF) ligand superfamily that plays a significant role in immune regulation and tumor biology. As a transmembrane protein, APRIL is involved in modulating immune responses, B-cell development, and tumor cell proliferation, making it a promising target for immunotherapy and cancer research. Structure and Function APRIL is synthesized as a membrane-bound 32 kDa proprotein, which is cleaved by furin in the Golgi apparatus to release a bioactive 17 kDa soluble protein. It primarily consists of a TNF homology domain, which facilitates binding to its receptors, such as BCMA and TACI, to regulate immune cell activity. It interacts with heparan sulfate proteoglycans (HSPGs), which induce oligomerization and enhance its effects on immune cells and tumor growth.​ Role in Immune Regulation and Cancer APRIL influences B-cell activation, proliferation, and the production of antibodies, contributing to both protective immune responses and autoimmune processes. Elevated levels of APRIL are observed in various cancers and tumor-infiltrating neutrophils, promoting tumor growth and survival. In autoimmune disorders, APRIL has a dual role, supporting humoral immunity while also inhibiting pathological responses in certain contexts.​ Therapeutic Potential Due to its involvement in tumor progression and immune modulation, APRIL is an attractive target for developing immunotherapies aimed at controlling cancer and autoimmune diseases. Recombinant APRIL proteins are utilized in preclinical research to study its effects on tumor cell proliferation, immune cell activation, and as a tool for drug screening.